Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer--results of a first-in-man dose-escalation study with a fixed-dose extension phase
Isambert, N., Delord, J.- P., Soria, J.- C., Hollebecque, A., Gomez-Roca, C., Purcea, D., Rouits, E., Belli, R., Fumoleau, P.Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv031
Date:
May, 2015
File:
PDF, 206 KB
english, 2015